Alice Cani

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1661233/publications.pdf

Version: 2024-02-01

20	572	840119 11	940134 16
papers	citations	h-index	g-index

20	20	20	1082
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effects of Ultra-Short Pulsed Electric Field Exposure on Glioblastoma Cells. International Journal of Molecular Sciences, 2022, 23, 3001.	1.8	7
2	Histone Deacetylase Inhibitors Impair Glioblastoma Cell Motility and Proliferation. Cancers, 2022, 14, 1897.	1.7	11
3	Customized bioreactor enables the production of 3D diaphragmatic constructs influencing matrix remodeling and fibroblast overgrowth. Npj Regenerative Medicine, 2022, 7, 25.	2.5	5
4	Targeting mesenchymal stromal cells plasticity to reroute acute myeloid leukemia course. Blood, 2021, 138, 557-570.	0.6	26
5	Hydrogen peroxide toxicity on auditory cells: An in vitro study. Chemico-Biological Interactions, 2021, 345, 109575.	1.7	11
6	Case Report: Intestinal Nodular Lymphoid Hyperplasia as First Manifestation of Activated PI3KÎ´ Syndrome Due to a Novel PIK3CD Variant. Frontiers in Pediatrics, 2021, 9, 703056.	0.9	5
7	HIF-1Î±/Wnt signaling-dependent control of gene transcription regulates neuronal differentiation of glioblastoma stem cells. Theranostics, 2019, 9, 4860-4877.	4.6	29
8	Somatic mutations activating Wiskott-Aldrich syndrome protein concomitant with RAS pathway mutations in juvenile myelomonocytic leukemia patients. Human Mutation, 2018, 39, 579-587.	1.1	16
9	miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model. Molecular Therapy - Nucleic Acids, 2018, 11, 485-493.	2.3	81
10	Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia. Oncotarget, 2015, 6, 6597-6610.	0.8	27
11	The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells. Oncotarget, 2015, 6, 17147-17160.	0.8	30
12	Abstract B46: Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent AKT reactivation. , 2015, , .		0
13	Abstract A34: Therapeutic potential of the novel mTOR inhibitor Torin-2 to overcome AKT reactivation in B-precursor acute lymphoblastic leukemia (B-pre ALL).. , 2015, , .		0
14	Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential. Leukemia, 2014, 28, 739-748.	3.3	107
15	Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. Oncotarget, 2014, 5, 10034-10047.	0.8	60
16	The AKT Inhibitor MK-2206 is Cytotoxic in Hepatocarcinoma Cells Displaying Hyperphosphorylated AKT-1 and Synergizes with Conventional Chemotherapy. Oncotarget, 2013, 4, 1496-1506.	0.8	47
17	Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia, 2012, 26, 2336-2342.	3.3	76
18	Abstract 3750: The novel Akt inhibitor MK-2206, is cytotoxic in T-cell acute lymphoblastic leukemia: Therapeutic implications. , 2012, , .		1

#	Article	IF	Citations
19	Abstract 3736: The mTOR inhibitor, RAD001, displays higher cytotoxicity in leukemias with hyperactivated PI3K/AKT/mTOR pathway. , 2012, , .		0
20	Epstein-Barr virus-specific antibody response in cerebrospinal fluid and serum of patients with multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 883-887.	1.4	33